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Meritxell Sabidó e, Nicholas Everage f, Kiliana Suzart-Woischnik g, Riho Klement h, Jan Hillert i, 
Auli Verkkoniemi-Ahola j, Shahram Bahmanyar k,l,m, Scott Montgomery n,o,p, Pasi Korhonen q, 
European Interferon Beta Pregnancy Study Group and the Nordic MS Pregnancy & Interferon 
Beta study group 
a StatFinn-EPID Research, Paldiski mnt 29, 10612, Tallinn, Estonia 
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Adverse pregnancy outcomes 
Stratification 
A B S T R A C T   
Background: Previous studies reported no increase in the prevalence of adverse pregnancy outcomes after 
exposure to interferon-beta (IFN-beta). However, no study has investigated if the prevalence of these outcomes 
after IFN-beta exposure is modified by maternal and newborn characteristics. Our objective was to describe the 
stratified prevalence of adverse pregnancy outcomes among women with multiple sclerosis (MS) exposed only to 
IFN-beta or unexposed to any MS disease modifying drugs (MSDMDs). 
Methods: This population-based cohort study using Finnish (1996-2014) and Swedish (2005-2014) register data 
included pregnancies of women with MS exposed only to IFN-beta 6 months before or during pregnancy (n=718) 
or unexposed to MSDMDs (n=1397). The outcome prevalences were described stratified by maternal and 
newborn characteristics, with 95% confidence intervals (CIs). Confounder-adjusted analyses were performed if 
the prevalence results indicated modified effect of IFN-beta in specific strata. 
Results: The stratified analysis indicated that the prevalence of serious (anomaly or stillbirth) and other adverse 
pregnancy outcomes was similar among the exposed and unexposed, with no statistically significant difference. 
Among women treated for MS >5 years, serious adverse pregnancy outcomes occurred in 4.3% (95%CI: 1.9- 
8.3%) of pregnancies exposed only to IFN-beta 6 months before or during pregnancy and in 2.7% (95%CI: 1.2- 
5.0%) of unexposed pregnancies. The confounder adjusted analyses did not support the hypothesis that MS 
* Corresponding author at: StatFinn – EPID Research, Prästgårdsgatan 28, 431 44 Mölndal, Sweden. 
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treatment duration before pregnancy would modify the risk of adverse pregnancy outcomes after exposure to 
IFN-beta 6 months before or during pregnancy. 
Conclusion: The prevalence of adverse pregnancy outcomes was not increased after IFN-beta exposure, when 
pregnancies of women with MS were stratified by maternal and newborn characteristics. The stratified results 
were similar to the unstratified results in the same population.   
1. Introduction 
Multiple sclerosis (MS) is the most common chronic neurological 
disease in women of childbearing age, with treatment initiation rec-
ommended at an early disease stage (Banwell et al., 2019). Among 
several MS disease-modifying drugs (MSDMDs) that have been approved 
(Ransohoff et al., 2015), interferon-beta (IFN-beta) (European Medi-
cines Agency EMA, 2019a; European Medicines Agency EMA, 2019b; 
European Medicines Agency EMA, 2019c; European Medicines Agency 
EMA, 2019d; European Medicines Agency EMA, 2020a) has been used to 
treat MS for the last 20 years (Montalban et al., 2018) with favourable 
benefit-risk profiles. Since September 2019, IFN-beta use may be 
considered during pregnancy, if clinically needed (European Medicines 
Agency EMA, 2019a; European Medicines Agency EMA, 2019b; Euro-
pean Medicines Agency EMA, 2019c; European Medicines Agency EMA, 
2019d; European Medicines Agency EMA, 2020a). 
Previous observational studies (Thiel et al., 2016; Hellwig et al., 
2012; Romero et al., 2015; Coyle et al., 2014; Sandberg-Wollheim et al., 
2011; Amato et al., 2010; Weber-Schoendorfer and Schaefer, 2009; 
Patti et al., 2008; Hellwig et al., 2020a; Hellwig et al., 2020b) and a large 
post-authorisation safety study (PASS) (EPID Multiple Sclerosis Preg-
nancy study, 2020) in women with MS have reported no increase in the 
Fig. 1. Included pregnancy outcome events. 
aUsed as a denominator in this study. 
bContributed to the alternative unexposed group: unexposed to IFN-beta regardless of exposure to other MSDMDs, N=1692 (Unexposed to any MSDMDs, N=1397 +
Unexposed to IFN-beta and exposed to other MSDMDs, N=295). 
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prevalence of adverse pregnancy outcomes after exposure to IFN-beta 
before or during pregnancy. Data from Finland, however, suggest that 
the prevalence of elective terminations for reasons other than foetal 
anomaly may be increased among pregnant women exposed to IFN-beta 
(EPID Multiple Sclerosis Pregnancy study, 2020). No prior study has 
investigated the prevalence of adverse birth outcomes among IFN-beta 
exposed women stratified into subgroups by maternal and newborn 
characteristics, apart from describing them as risk factors of adverse 
pregnancy outcomes (Amato et al., 2010; World Health Organization, 
2016). Stratified analyses would inform whether the prevalence of 
adverse pregnancy outcomes after IFN-beta exposure is modified by 
certain maternal characteristics or if the prevalence by exposure status 
differs according to newborn characteristics. 
The objective of this large population-based cohort study, using 
register data, was to describe the prevalence of adverse pregnancy 
outcomes among pregnancies of women with MS exposed only to IFN- 
beta and those unexposed to any MSDMD, with stratification by 
maternal and newborn characteristics. 
2. Material and methods 
2.1. Study design, setting, and participants 
This cohort study was part of the recently conducted PASS (EPID 
Multiple Sclerosis Pregnancy study, 2020), utilising national registers in 
Finland and Sweden. The data were extracted on women with MS (In-
ternational Classification of Diseases 10th revision; ICD-10 code G35) 
who were pregnant during the study period: 01 January 1996 – 31 
December 2014 in Finland and 01 July 2005 – 31 December 2014 in 
Sweden. Pregnancies ending in elective termination (only in Finland), 
stillbirth, or live birth during the study period were included in this 
cohort study population. Ectopic pregnancies and spontaneous abor-
tions, included in the main analysis of the PASS (EPID Multiple Sclerosis 
Pregnancy study, 2020), were excluded from this study population due 
to incomplete information on key variables, including gestational age, 
and due to the inability to detect all spontaneous abortions using 
healthcare data. Most early spontaneous abortions do not involve an 
interaction with healthcare, and, thus are not recorded. Late sponta-
neous abortions might be managed in primary care, which is not 
included in the used registries. Exclusively, pregnancies for which 
exposure status (as defined below) could be defined were included. If 
women had multiple pregnancy events during the study period or 
multifetal gestations, all pregnancies, births, and foetuses were 
included, the exposure status was defined separately for each pregnancy, 
and the outcomes of each foetuses were considered separately. The study 
was approved by the Helsinki University Hospital Ethics Committee 
(Finland; 159/13/03/00/2016) and the Regional Ethical Review Board 
in Stockholm (Sweden; 2016/874-31/2). 
2.2. Data sources and data linkage 
Extracted data from the healthcare registers were linked with a 
unique personal identification number. The healthcare registers 
included the Care Register for Health Care (Finnish Institute for Health 
and Welfare THL, 2016), Medical Birth Register (Finnish Institute for 
Health and Welfare THL, 2019), Register on Induced Abortions (Finnish 
Institute for Health and Welfare THL, 2020a), Register of Congenital 
Malformations (Finnish Institute for Health and Welfare THL, 2020b), 
Special Reimbursement Register (SRR) (Social Insurance Institution 
(Kela), 2020a), and National Prescription Register (Social Insurance 
Institution (Kela), 2020b) in Finland, and the National Patient Register 
(National Board of Health and Welfare (Socialstyrelsen), 2019a), Med-
ical Birth Register (National Board of Health and Welfare (Social-
styrelsen), 2019b), Swedish Prescribed Drug Register (SPDR) 
(Wettermark et al., 2007), and Swedish MS Register (Hillert and Sta-
wiarz, 2015) in Sweden. 
2.3. Variables 
2.3.1. Exposure 
Pregnant women were considered exposed only to IFN-beta if an IFN- 
beta product (with Anatomical Therapeutic Chemical codes L03AB07, 
L03AB08, L03AB13) had been dispensed from the pharmacy, without 
any dispensation of another MSDMD (Appendix A.1), within 6 months 
before the last menstrual period (LMP) or during pregnancy. In Finland, 
dispensed drugs were captured from the SRR, and in Sweden from the 
SPDR and the Swedish MS Register. Including dispensations 6 months 
before LMP enabled capturing exposure within 3 months of LMP, as 
patients in Finland and Sweden are typically dispensed chronic medi-
cations in 3-month intervals. Women without dispensation of an IFN- 
beta product or any another MSDMD in the 6 months prior to LMP or 
during pregnancy were considered unexposed, with a prolonged pur-
chase period of 9 months before LMP for mitoxantrone and cladribine 
tablets. 
Table 1 
Maternal characteristics for the pregnancy outcome events ending in elective 
termination (only in Finland), stillbirth, or live birth, which were exposure only 
to IFN-beta 6 months before or during pregnancy or unexposed to any MSDMDs  
Maternal characteristics Pregnancy outcome events ending in 
elective termination (only in Finland), 
stillbirth, or live birth 
Pregnancy events, N 2115 
Country of residence 
Finland, n (%) 769 (36.4) 
Sweden, n (%) 1346 (63.6) 
Year of pregnancy outcome 
1996-1999, n (%) 45 (2.1) 
2000-2004, n (%) 58 (2.7) 
2005-2009, n (%) 675 (31.9) 
2010-2014, n (%) 1337 (63.2) 
Maternal age at LMP 
≤20 years, n (%) 20 (0.9) 
21-25 years, n (%) 219 (10.4) 
26-30 years, n (%) 688 (32.5) 
31-35 years, n (%) 819 (38.7) 
36-40 years, n (%) 327 (15.5) 
> 40 years, n (%) 
Mean (± SD) 
42 (2.0) 
31.2 (4.6) 
Any chronic disease before or 
during pregnancy (excl. MS)a, n 
(%) 
798 (37.7) 
Exposure to any teratogenic medications beforeb or during pregnancyc 
group C, n (%) 1202 (56.8) 
group D, n (%) 302 (14.3) 
Time since MS diagnosis  
≤2 years, n (%) 616 (29.1) 
3-5 years, n (%) 718 (33.9) 
>5 years, n (%) 
Mean, years (± SD) 
781 (36.9) 
4.5 (3.7) 
Duration of MS treatmentd 
≤2 years, n (%) 777 (36.7) 
3-5 years, n (%) 578 (27.3) 
>5 years, n (%) 525 (24.8) 
IFN-beta, interferon beta; MS, multiple sclerosis; n, number of pregnancy 
outcome events; MSDMD, multiple sclerosis disease modifying drug; LMP, last 
menstrual period; MS, multiple sclerosis; SD, standard deviation. 
a List of chronic diseases (excl. MS) listed in Appendix A.3. 
b Six months before LMP. 
c Teratogenic C and D drugs are based on year 2017 list in Sweden (Appendix 
A.4). 
d Duration of MS treatment at LMP refers to refers to any MS treatment the 
patient may have ever received. 
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2.3.2. Outcomes 
The primary outcome variable was the composite serious adverse 
pregnancy outcome, defined as elective termination of pregnancy due to 
foetal anomaly (TOPFA), or live birth with a major congenital anomaly 
(MCA), or stillbirth. Of other outcomes, MCA total included TOPFA, 
MCA in live births, and also MCA in stillbirths but excluded other still-
births. Other outcomes were MCA in live births only; elective termination 
for reasons other than foetal anomaly; TOPFA only; stillbirth only; and non- 
live birth (combining elective terminations for any reasons and still-
births). MCA was defined as ICD codes (9th revision; ICD-9) 740-759, 
divided into 25 groups, with minor anomalies excluded according to 
the European Surveillance of Congenital Anomalies (EUROCAT). For 
live births, the MCA diagnosis was followed-up for 12 months in Finland 
and 6 months in Sweden. Stillbirths were defined as the death of foetus 
with birth weight of ≥500 grams or ≥22+0 gestational weeks, and 
elective termination as ICD-10 code O04 (available only in Finland). 
2.3.3. Maternal and newborn characteristics 
The maternal characteristics used for stratification (Appendix A.2) 
were country of residence, year of pregnancy outcome, maternal age at 
LMP, time since MS diagnosis, duration of MS treatment, any chronic 
diseases (Appendix A.3), and exposure to any teratogenic medications 
(Appendix A.4). As described in Appendix A.2, the duration of MS 
treatment was defined as the time in years between the start of any 
MSDMD treatment (IFN-beta or another MSDMD, as in Appendix A.1) 
and LMP, regardless of exposure status 6 months before or during 
pregnancy. The newborn characteristics (Appendix A.2) included 
gestational age at pregnancy outcome and birth weight, which were 
reported for pregnancy outcomes other than elective terminations. The 
stratification variables were pre-defined in the study protocol (EPID 
Multiple Sclerosis Pregnancy study, 2020), which was registered before 
the analyses. 
2.4. Statistical analyses 
The number and point prevalence (%) of the study outcomes were 
described for pregnancies exposed only to IFN-beta and unexposed to 
any MSDMD, and stratified by the maternal and newborn characteristics 
(EPID Multiple Sclerosis Pregnancy study, 2020). Stratification by 
maternal characteristics was performed for all outcomes, and stratifi-
cation by newborn characteristics for outcomes other than elective ter-
minations. The prevalence was presented with 95% confidence intervals 
(CI) using the Pearson-Clopper method. When the 95% CIs for the 
prevalence estimates for the exposed and unexposed pregnancies over-
lapped within a stratum, the outcome prevalence was considered not to 
differ with statistical significance between the exposed and unexposed 
pregnancies in that stratum. All results are reported per pregnancy 
outcome event (Appendix A.5). A missing category was included in the 
Fig. 2.1. Prevalence of serious adverse pregnancy outcomes (IFN-beta only exposed N=718 pregnancies; unexposed N=1397 pregnancies) stratified by maternal 
characteristics, among pregnancies exposed only to IFN-beta 6 months or during pregnancy and among those unexposed to any MSDMDs. 
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analysis for variables with missing data. In further analyses, an alter-
native definition of the unexposed pregnancies was used, wherein we 
considered pregnancies unexposed to exclusively IFN-beta instead of 
pregnancies unexposed to any MSDMDs. 
Additional confounder adjusted post hoc analyses further investi-
gated whether the effect of IFN-beta exposure is modified by maternal 
characteristics, as detailed in Appendix A.6. The analyses were consid-
ered for the most prevalent outcomes if effect modification was sus-
pected due to differing pattern of point prevalences for an adverse 
pregnancy outcome among the exposed and unexposed, when 
comparing the results in strata of a maternal characteristic to the 
unstratified results (Hakkarainen et al., 2020). 
2.5. Data statement 
According to the registered study protocol (EPID Multiple Sclerosis 
Pregnancy study, 2020), access to the study data cannot be given to any 
third parties, and the study data cannot be used for purposes other than 
described in this protocol. All requests to use the study data for other 
purposes than mentioned in this study protocol must be subjected to 
appropriate data permit processes. 
3. Results 
The study population included 2,115 pregnancies ending in elective 
termination (only in Finland), stillbirth, or live birth (Fig. 1), and being 
exposed only to IFN-beta (n=718) or unexposed to any MSDMDs 
(n=1,397). The maternal age at LMP was most commonly within the age 
group of 31-35 years (38.7%) (Table 1). Other chronic diseases before or 
during pregnancy were reported in 37.7% of the pregnancies. The time 
since MS diagnosis and time since the start of any MSDMD treatment 
before the pregnancy was >5 years in 36.9% and 24.8% of the preg-
nancies, respectively. 
3.1. Maternal characteristics 
When stratifying by maternal characteristics, the prevalence of the 
primary outcome (i.e. composite serious adverse pregnancy outcome) was 
similar among pregnancies exposed only to IFN-beta and those unex-
posed to any MSDMDs, with no statistically significant difference, as 
indicated by the overlapping 95% CIs for the prevalence estimates 
(Fig. 2.1). Within each stratum except for the women treated for MS >5 
years, the point prevalence of the composite primary outcome was lower 
among pregnancies exposed only to IFN-beta compared to the unex-
posed women; however, the comparisons were not statistically 
Fig. 2.2. Prevalence of MCA total (IFN-beta only exposed N=718 pregnancies; unexposed N=1397 pregnancies) stratified by maternal characteristics, among 
pregnancies exposed only to IFN-beta 6 months or during pregnancy and among those unexposed to any MSDMDs. 
CI, confidence interval; IFN-beta, interferon beta; LMP, last menstrual period; MCA, major congenital anomaly; MS, multiple sclerosis; n, number of pregnancy 
outcome events. 
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significant. Among women treated for MS >5 years, serious adverse 
pregnancy outcomes occurred in 4.3% (95% CI: 1.9-8.3%) of pregnancies 
exposed only to IFN-beta and in 2.7% (95% CI: 1.2-5.0%) of pregnancies 
unexposed to any MSDMDs. When stratifying by maternal age, the point 
prevalence for the composite outcome appeared to decrease with 
increasing age among pregnancies exposed only to IFN-beta and was 
similar across the age groups among the unexposed pregnancies, how-
ever, overlapping CIs indicate no statistical difference of the observed 
trend. 
The descriptive prevalence of MCA total was similar between the 
pregnancies exposed only to IFN-beta and unexposed to any MSDMDs 
when stratified by maternal characteristics (Fig. 2.2), with a trend 
within each stratum towards lower point prevalence among pregnancies 
exposed to IFN-beta compared to those which were the unexposed. The 
prevalence of MCA total among women treated for MS >5 years was 
3.7% (95% CI: 1.5-7.6%) for the pregnancies exposed only to IFN-beta, 
and 2.1% (95% CI: 0.8-4.2%) for those unexposed to any MSDMDs. The 
prevalence of MCA in live births stratified by maternal characteristics 
(Appendix Fig. B.1) was consistent with those for MCA total. 
The point estimate for the prevalence of elective termination for other 
reasons than foetal anomaly was higher among pregnancies exposed only 
to IFN-beta than among pregnancies unexposed to any MSDMDs in most 
of the maternal characteristics strata, although the comparisons were 
not statistically significant (Fig. 2.3). During 2000-2004, elective termi-
nations for reasons other than foetal anomaly were particularly frequent 
among the pregnancies exposed to only IFN-beta (34.6%, 95% CI: 17.2- 
55.7%) vs unexposed (6.2%, 95% CI: 0.8-20.8%). In the years 1996- 
1999, one pregnancy was exposed to only IFN-beta and the pregnancy 
was terminated (100.0%), but the presence of only one case led to very 
low precision (95% CI: 2.5-100.0%). For elective TOPFA, the stratifi-
cation also led to a low number of outcomes per stratum, and thereby a 
low precision (wide 95% CIs) of the prevalence estimates (Appendix Fig. 
B.2). 
In the strata of varying maternal characteristics, the prevalence of 
stillbirths was similar between the pregnancies exposed only to IFN-beta 
and those unexposed to any MSDMDs. It is worth noticing that the total 
number of stillbirth cases was low (n=10), which is reflected in the low 
number and prevalence of stillbirths for several strata (Fig. 2.4). The 
prevalence of non-live births, across the strata, appeared increased for the 
IFN-beta exposed pregnancies (Appendix Fig. B.3). 
3.2. Newborn characteristics 
When stratifying by newborn characteristics, the prevalence of the 
composite serious adverse pregnancy outcome (Fig. 3.1), MCA total 
(Fig. 3.2), and MCA in live births (Appendix Fig. C.1) was similar among 
Fig. 2.3. Prevalence of elective terminations for other reasons than foetal anomaly (IFN-beta only exposed N=295 pregnancies; unexposed N=474 pregnancies; data 
available exclusively in Finland) stratified by maternal characteristics, among pregnancies exposed only to IFN-beta 6 months or during pregnancy and among 
those unexposed to any MSDMDs. 
CI, confidence interval; IFN-beta, interferon beta; LMP, last menstrual period; MS, multiple sclerosis; n, number of pregnancy outcome events. 
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pregnancies exposed only to IFN-beta and those unexposed to any 
MSDMDs, with no statistically significant differences between the two 
exposure groups. In the strata of newborns with gestational age of <28 
and ≥37 weeks, the point prevalence of the composite outcome, MCA 
total, and MCA in live births appeared lower among pregnancies exposed 
only to IFN-beta compared to pregnancies unexposed to any MSDMDs. 
In the stratum of newborns with gestational age of 28-36 weeks, the 
point prevalence of these outcomes appeared higher when pregnancies 
were exposed only to IFN-beta than for pregnancies unexposed to any 
MSDMDs; however, few outcomes in the stratum led to poor precision 
(serious adverse pregnancy outcome, n=3, 7.1% (95% CI: 1.5-19.5%) vs 
n=5, 4.8% (95% CI: 1.6-10.8%); MCA total, n=3, 7.1% (95% CI: 1.5- 
19.5%) vs n=4, 3.8% (95% CI: 1.0-9.5%); MCA in live births, n=3, 7.1% 
(95% CI: 1.5-19.5%) vs n=3, 3.8% (95% CI: 1.1-9.6%)). 
The prevalence of stillbirths (Fig. 3.3) and non-live births (Appendix 
Fig. C.2), stratified by newborn characteristics, also appeared to be 
similar between the pregnancies exposed only to IFN-beta and those 
unexposed to any MSDMDs. However, the strata had very few outcomes 
considering that in total only 2 stillbirths were observed among the 718 
exposed and 8 stillbirths among the 1397 unexposed pregnancies. 
3.3. Analysis with an alternative definition of unexposed 
In the analyses using the alternative definition of unexposed, the 
stratified prevalence of adverse pregnancy outcomes remained consis-
tent with the main analyses (Appendix Tables D1-D7). 
3.3.1. Post hoc analyses 
The post hoc analyses were performed for the maternal characteristic 
‘duration of MS treatment’, which was the only characteristic that was 
suspected to potentially modify the effect of exposure to IFN-beta, for 
the following outcomes: serious adverse pregnancy outcomes, MCA total, 
and MCA in live births. Firstly, the likelihood ratio test demonstrated 
statistically significant interaction between ‘duration of MS treatment’ 
and exposure status (p-values for serious adverse pregnancy outcome 
0.023; MCA total 0.027; MCA in live births 0.025), which indicated that 
‘duration of MS treatment’ might modify the effect of the outcomes, i.e. 
that the prevalence of serious adverse pregnancy outcomes, MCA total, and 
MCA in live births might differ based on the duration of the mother’s MS 
treatment before pregnancy. 
Secondly, when an interaction between the exposure status (exposed 
to IFN-beta only or unexposed to any MSDMDs 6 months before or 
during pregnancy) and ‘duration of MS treatment’ was assessed in the 
entire study population (adjusted model with an interaction term), the 
ORs for the outcomes showed a gradual increase with an increase in the 
duration of MS treatment among pregnancies exposed to IFN-beta only 6 
months before or during pregnancy, as compared to those unexposed to 
any MSDMDs 6 months before or during pregnancy wherein the mother 
had been treated for MS for ≤2 years before pregnancy (Appendix Table 
D8). The trend was opposite for the pregnancies unexposed to any 
MSDMDs 6 months before or during pregnancy: the ORs for the out-
comes were lower when the mother had been treated for MS for >5 years 
before pregnancy, compared with being treated for ≤2 years before 
pregnancy. In these adjusted models with the interaction terms, how-
ever, the 95% CIs for all of the ORs were wide and overlapped with each 
other, which indicates low precision and high uncertainty in the 
observed effects of the duration of the mother’s MS treatment before 
pregnancy. 
Thirdly, when the exposed vs unexposed pregnancies were compared 
separately within each stratum of ‘duration of MS treatment’, the 
adjusted ORs for the outcomes serious adverse pregnancy outcomes, MCA 
total, and MCA in live births were comparable between the two strata 
with shorter treatment durations before the pregnancy, i.e. ≤2 years and 
3-5 years (Appendix Table D9). For all of these outcomes, there was an 
increase in the ORs within the stratum of women with MS who had been 
treated for >5 years before the pregnancy. However, the wide and 
overlapping 95% CIs associated with their ORs do not support this in-
crease in the outcome prevalence in the stratum with the longest 
treatment duration would have been statistically significant. 
4. Discussion 
After stratification by maternal and newborn characteristics, the 
descriptive prevalence of serious adverse pregnancy outcomes or other 
pre-specified outcomes did not appear higher with IFN-beta exposure 
before or during pregnancy relative to those unexposed to any MSDMDs. 
4.1. Maternal characteristics 
Our result indicated that the descriptive prevalence of serious and 
other adverse pregnancy outcomes was not increased among pregnan-
cies exposed to IFN-beta in the strata of maternal characteristics, which 
is consistent with the unstratified results in the same population (EPID 
Multiple Sclerosis Pregnancy study, 2020; Hakkarainen et al., 2020). 
The finding that in some strata the prevalence appeared decreased 
among the pregnancies exposed only to IFN-beta compared to preg-
nancies unexposed to any MSDMDs, without statistical significance, may 
have been caused by underlying factors that were unfavourable among 
the unexposed women and that this study using the available register 
data could not detect (e.g., life-style factors (beyond BMI), maternal 
alcohol and substance use, or actual use of teratogenic drugs before and 
during pregnancy). Overall, this PASS was designed to assess the safety 
of IFN-beta use during pregnancy and to detect the possible increase of 
adverse outcomes, with pre-defined objectives and analyses (EPID 
Multiple Sclerosis Pregnancy study, 2020). Thus, interpretations focus 
on a possible increase in the prevalence of adverse pregnancy outcomes. 
Although the descriptive prevalence of elective terminations for 
reasons other than foetal anomaly appeared to be higher among exposed 
pregnancies across the strata of maternal characteristics, the over-
lapping CIs for the exposed and unexposed indicate no statistically sig-
nificant difference. In general, reasons for such elective terminations, 
available exclusively from Finland, include social reasons, such as either 
young or old age, and medical reasons related to the foetus or a parent 
(Väisänen, 2015). The high frequency of elective terminations for rea-
sons other than foetal anomaly among the IFN-beta exposed pregnancies 
in years 2000-2004 and 1996-1999 probably attributed to the stricter 
contraindication in treatment guidelines at the time, concerning the use 
of IFN-beta during pregnancy, and more conservative clinical practice 
(European Medicines Agency EMA, 2020b, European Medicines Agency 
EMA, 2020c). Since then and still during the study period (until 2014), 
more evidence has been published on the safety of IFN-beta use during 
pregnancy (Hellwig et al., 2012; Romero et al., 2015; Coyle et al., 2014; 
Sandberg-Wollheim et al., 2011; Amato et al., 2010; Weber--
Schoendorfer and Schaefer, 2009; Patti et al., 2008), which has likely 
impacted clinicians’ recommendations and maternal decision-making 
and led to a decreasing frequency of elective terminations over time. 
The high frequency of elective terminations for reasons other than foetal 
anomaly among the IFN-beta only exposed pregnancies also led to a high 
frequency of non-live births among the pregnancies exposed only to 
IFN-beta. The low number of stillbirths (also included in the definition of 
non-live births) hindered observing patterns in the prevalence of 
stillbirths. 
These descriptive results indicate that none of the maternal charac-
teristics had a statistically relevant impact as effect modifiers on the 
prevalence of adverse pregnancy outcomes among the pregnancies 
exposed only to IFN-beta. Thus, this study informs about the homoge-
neity and commonality of the effect that IFN-beta has when used during 
pregnancy regardless of the characteristics of the mother (Rothman 
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et al., 2008). 
Although we detected a numerically higher point prevalence of 
serious adverse pregnancy outcomes and MCAs among the IFN-beta 
exposed pregnancies of women treated for MS for >5 years before the 
pregnancy, compared to the pregnancies unexposed to any MSDMDs, 
the presence of effect modification by duration of MS treatment is un-
likely. If the duration of MS treatment was an effect modifier, as defined 
by Rothman et al. (2008), the risk of serious adverse pregnancy out-
comes and MCAs after IFN-beta exposure would vary across the strata by 
treatment duration. Our post hoc analyses with confounder adjustment 
did not support the presence of such effect modification, especially 
acknowledging probable residual confounding despite the confounder 
adjustment. Further, an increased risk of adverse outcomes in the 
pregnancies of women who were treated with IFN-beta during preg-
nancy and who had been for >5 years before pregnancy is unlikely based 
on medical plausibility, because these women are likely to have stable 
MS disease and be in good overall health. 
4.2. Newborn characteristics 
After stratification by newborn characteristics, our results were also 
consistent with the unstratified results in the same population (Hak-
karainen et al., 2020), with no increased prevalence estimates among 
the exposed pregnancies. Although newborns born within 28-36 weeks 
of gestation had a numerically higher prevalence of MCAs and the 
composite serious adverse pregnancy outcomes in the IFN-beta exposed 
pregnancies, the result was based on few outcomes per stratum and the 
precision of the prevalence was low. Thus, it cannot be concluded that 
these outcomes would be more prevalent among the IFN-beta exposed 
pregnancies than the unexposed pregnancies when the child is born 
early. Irrespective of IFN-beta exposure, the study finding that the 
prevalence of MCA was higher in live births of earlier gestational age is 
biologically plausible and supported by literature (Honein et al., 2009). 
4.3. Clinical significance 
The stratified analysis results of this large cohort study mirror the 
unstratified findings in the same population (EPID Multiple Sclerosis 
Pregnancy study, 2020; Hakkarainen et al., 2020), that IFN-beta expo-
sure before or during pregnancy does not appear to be harmful for the 
child. Thus, this study provides additional evidence on the safety of 
prescribing IFN-beta treatment for women with MS who are planning 
pregnancy, until the pregnancy is confirmed or even beyond, if the risk 
of relapse and disability accumulation during pregnancy needs to be 
reduced. The findings of this PASS cohort (EPID Multiple Sclerosis 
Pregnancy study, 2020, Hakkarainen et al., 2020) also led to a label 
change in the European Union, according to which IFN-beta products 
may now be considered during pregnancy, if clinically needed. 
Fig. 2.4. Prevalence of stillbirths (IFN-beta only exposed N=718 pregnancies; unexposed N=1397 pregnancies) stratified by maternal characteristics, among 
pregnancies exposed only to IFN-beta 6 months or during pregnancy and among those unexposed to any MSDMDs. 
CI, confidence interval; IFN-beta, interferon beta; LMP, last menstrual period; MS, multiple sclerosis; n, number of pregnancy outcome events. 
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The results obtained in this study can also be considered generaliz-
able in the Nordic countries other than Finland and Sweden. This could 
be considered based on that maternal characteristics of pregnant women 
with MS are expected to be similar between the Nordic countries and 
that the Nordic countries have similar population structures, healthcare 
systems with universal healthcare (including free-of-charge maternal 
care), and are welfare societies with small socioeconomic differences. 
The results of the current study may not be fully generalizable to other 
countries and regions with differing maternal characteristics (e.g., a 
higher BMI, as found in the United Kingdom (Euro-Peristat Project, 
2018)), population structures, healthcare systems, and societies con-
sisting of people who share a different common culture. The results are 
likely more generalizable in countries similar to Finland and Sweden. 
4.4. Methodological considerations 
Our study is, the first in our knowledge to investigate the prevalence 
of adverse pregnancy outcomes among pregnant women with MS 
exposed and unexposed to IFN-beta, stratified by maternal and newborn 
characteristics. Our results are strengthened by the national coverage of 
the Finnish and Swedish registers, the inclusion of an exhaustive MS 
patient pool, high quality register data (Finnish Institute for Health and 
Welfare THL, 2020c), and the long study period that allowed inclusion 
of over 2,000 pregnancies. The stratified prevalences, however, should 
be interpreted with caution as the descriptive prevalences were not 
controlled for confounding in the main analyses, which should be 
considered as one of the study limitations. An additional limitation was 
the low number of pregnancies and outcomes in several strata, which 
limit us from drawing definite conclusions, especially for the least 
prevalent outcomes: elective TOPFA and stillbirths. More specifically, 
the absence of statistically significant findings was likely contributed by 
lack of statistical power. However, this study included the entire pop-
ulation of pregnancies matching our inclusion criteria, for both Finland 
and Sweden, reducing concerns relating to sample size, which in general 
applies to probability sampling rather than whole population studies. 
However, stratified analyses performed on larger populations could 
prove beneficial in order to confirm the findings of our study. 
Our descriptive results are also strengthened by the post-hoc analyses 
with confounder adjustments, in which the only suspected effect mod-
ifier, ‘duration of MS treatment’, was not found to modify the risk of 
adverse pregnancy outcomes after IFN-beta exposure. Yet, the post-hoc 
analysis result should be interpreted with caution due to probable re-
sidual confounding despite adjusting for several important potential 
confounding factors, and due to the low number of pregnancies and 
outcomes. 
An important limitation of this study is the exclusion of spontaneous 
Fig. 3.1. Prevalence of serious adverse pregnancy outcomes (IFN-beta only exposed N=718 pregnancies; unexposed N=1397 pregnancies) stratified by newborn 
characteristics, among pregnancies exposed only to the IFN-beta 6 months before or during pregnancy and among those unexposed. 
CI, confidence interval; IFN-beta, interferon beta; MS, multiple sclerosis; n, number of pregnancy outcome events. 
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abortions from the stratification, as described under methods. However, 
the spontaneous abortions were analysed in the unstratified analysis and 
reported accordingly (EPID Multiple Sclerosis Pregnancy study, 2020; 
Hakkarainen et al., 2020). Our results were also limited by the un-
availability of elective terminations in Sweden, as elective terminations 
were collected anonymously, without a possibility to link pregnancy 
outcomes to the exposure. Therefore, elective terminations were not 
available for analyses in any Swedish registers, which resulted in the 
descriptive prevalence generally appearing higher in Finland. 
As described previously (Hakkarainen et al., 2020), the use of 
dispensing data hindered the ability to establish whether the dispensed 
drugs were used and to identify administered drugs in hospitals, 
including infusible therapies and study drugs such as mitoxantrone. The 
limitation was more pronounced in Finland, where exclusively 
dispensing data was used, while in Sweden administered drugs in hos-
pitals could, to some extent, be detected from the MS Register. This 
limitation may have diluted possible differences in the outcome preva-
lence between the exposed and unexposed groups. However, a sensi-
tivity analysis reported in the registered PASS (EPID Multiple Sclerosis 
Pregnancy study, 2020) revealed that the results of the unstratified 
analyses (Hakkarainen et al., 2020) remained consistent when all 
pregnancies with intravenous medical treatment administered in 
hospital were considered as exposed to other MSDMDs. Thus, this lim-
itation did not hamper the conclusion of the PASS. 
Additionally, the use of the register data hindered establishing 
whether the dispensed drugs were actually used and, as a consequence, 
also the exact length of exposure to IFN-beta that the women had during 
pregnancy. Additional post-hoc analyses (results not shown) revealed 
that in only 2-4% of the pregnancies, the women were dispensed IFN- 
beta during the second or third trimester. In the interpretation of this 
study, the results should primarily be interpreted to represent IFN-beta 
exposure before and in early pregnancy. 
Further, the maternal characteristics in this study did not include 
variables on MS disease course and severity, such as Expanded Disability 
Status Scale (EDSS) score, because clinical variables on MS disease were 
available exclusively in Sweden (MS Register) at the time of designing 
the study, and these variables had also partial missingness. However, 
there is no rationale that differing MS disease course or EDSS alone 
would lead to adverse pregnancy outcomes (Thöne et al., 2017; Pozzilli 
et al., 2015), but might carry information on differing treatment ap-
proaches relevant for adverse pregnancy outcomes. Further information 
on the distribution of the included maternal characteristics in the 
unstratified population is available in the registered full study report 
(EPID Multiple Sclerosis Pregnancy study, 2020) and in the publication 
Fig. 3.2. Prevalence of MCA total (IFN-beta only exposed N=718 pregnancies; unexposed N=1397 pregnancies) stratified by newborn characteristics, among 
pregnancies exposed only to the IFN-beta 6 months before or during pregnancy and among those unexposed. 
CI, confidence interval; IFN-beta, interferon beta; MCA, major congenital anomaly; MS, multiple sclerosis; n, number of pregnancy outcome events. 
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of unstratified analyses (Hakkarainen et al., 2020). 
Finally, our study did not include the most recent years, due to the 
time required for accessing register data and conducting a large multi- 
country, multiple database study submitted to and reviewed by regu-
latory drug agencies. 
5. Conclusion 
The prevalence of adverse pregnancy outcomes was not increased 
after IFN-beta exposure before and during pregnancy, when pregnancies 
of women with MS were stratified by maternal and newborn charac-
teristics. The stratified results were similar to the unstratified results in 
the same population. 
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